Sanofi

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

The future of pharmaceutical investment lies in the convergence of ESG principles with a strong emphasis on positive social contribution, ethical AI, and innovative business models. Companies that successfully navigate this landscape will be well-positioned to lead the industry in both financial performance and societal impact.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

This new approach, powered by a specialised protein large language model, predicts the most effective protein variants while using 99% less data than traditional methods.

Macron aims to dedicate a gigawatt of nuclear power to create one of the world's largest AI-computing facilities.